From the Wires
Verisante Aura Named Finalist for 2013 SPIE Prism Award
By: Marketwired .
Nov. 20, 2012 01:41 PM
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 11/20/12 -- Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that Verisante's Aura(TM), the revolutionary skin cancer detection device, has been named a finalist for the 2013 Prism Awards in the Life Sciences and Biophotonics category.
"We are honoured to be a finalist for this prestigious Award," said Thomas Braun, President and CEO. "It is very gratifying to be recognized as an industry leader for our innovative and disruptive technology, which has the potential to improve patient outcomes, reduce wait times and also save the health care system time and money. The Aura is a game changing technology because in half a second it will tell doctors if a suspicious skin lesion is high or low risk for being cancerous and should be biopsied or not."
Verisante will be in attendance when the winner will be announced at the 2013 Prism Awards banquet on February 6 in San Francisco. The Verisante Aura(TM) beta units are currently installed at five leading dermatology clinics across Canada for software verification purposes. This is the final step prior to making this device available in Canada, 27 European countries, and Australia where the device has already been approved for sale. The Verisante Aura(TM) is expected to be commercially available in Canada, Europe and Australia in early 2013.
About the 2013 Prism Awards
The Prism Awards, named the "Photonics Oscar" by OptecNet Deutschland, is a celebration of the best of our industry. It takes place every year in conjunction with SPIE Photonics West in San Francisco, California.
The Prism Awards for Photonics Innovation is a leading international competition that honors the best new photonic products on the market. Over the years, the Prism Awards has received applications from more than 35 countries across the globe. Applications are judged by panel of leading industry experts, venture capitalists, luminaries and visionaries. The finalists and winners that are ultimately chosen (from General Electric, Agilent, Hamamatsu to Swamp Optics, Optotune, WiTec) reflect the diversity of the program.
SPIE Photonics West is the world's largest and most influential photonics and optics event with over 1500 companies exhibiting and 20,000 attendees.
To find out more about the Awards, visit the website at http://www.photonicsprismaward.com.
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura(TM) for skin cancer detection and the Verisante Core(TM) series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Aura(TM) has been approved for sale in Canada, Europe and Australia. The Core(TM) has not yet been approved for sale.
Verisante Aura(TM) was awarded Popular Science Magazine's "Best of What's New Award" for 2011, and Verisante Core(TM) was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. In addition, the Company was named a finalist for the 2011 Regional Awards for New Technology by the Canadian Manufacturers & Exporters and the National Research Council of Canada and named as the year's top ranking Technology and Life Sciences Company on the TSX Venture 50.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Latest AJAXWorld RIA Stories
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
SYS-CON Featured Whitepapers
Most Read This Week